News Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Real-time Estimate Cboe BZX Other stock markets 02:42:20 2024-05-28 pm EDT			5-day change	1st Jan Change
37.38 ^USD	+22.90%		+25.49%	+18.81%

May. 22	Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines	MT
May. 22	Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines	May. 22	MT
Achilles Therapeutics plc Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines	May. 22	CI
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine	May. 20	BU
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine	May. 20	PR
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences	May. 15	BU
Arcturus Therapeutics: Q1 Earnings Snapshot	May. 08	AQ
Transcript : Arcturus Therapeutics Holdings Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q1 Revenue $38M, vs. Street Est of $17.7M	May. 08	MT
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress	May. 08	BU
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024	Apr. 25	BU
Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	Mar. 27	MT
Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	Mar. 21	MT
Arcturus Therapeutics : Positive Results of Phase III Study of Bivalent Version of Kostaive®, Self-Amplifying mRNA Vaccine Against COVID-19 (Ancestral Strain and Omicron BA.4/5), for Booster Vaccination Conducted in Japan - Form 8-K	Mar. 19	PU
Transcript : Arcturus Therapeutics Holdings Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM	Mar. 14
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating	Mar. 11	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating	Mar. 08	MT
Transcript : Arcturus Therapeutics Holdings Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	Mar. 07	MT
Arcturus Therapeutics: Q4 Earnings Snapshot	Mar. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Summary

Filters